Alberta Record

· Bill / Drug Regulation Governance · tabled

Bill 29 — Ministerial Authority over Schedule 1 Drug Sales via Written Orders

Introduces a new framework for "written orders" for Schedule 1 drugs, granting the Minister broad powers to determine which drugs can be sold this way, their quantities, and associated procedures, with these ministerial orders explicitly e…

Moderate impactCentralization of powerHealth system governanceInstitutional independenceHealth-care bodiesThe public, directlyLegislature

What changed

  • The Pharmacy and Drug Act is amended to add a new Part 3.1, "Written Orders," for Schedule 1 drugs (Section 9(5)).
  • The Minister may, by order, determine which Schedule 1 drugs are authorized for sale by written order, set maximum quantities, and establish processes, procedures, limits, or restrictions (Section 9(5), new 29.3(1)).
  • Ministerial orders made under this new section are explicitly exempt from the Regulations Act (Section 9(5), new 29.3(2)).
  • New record-keeping requirements are introduced for pharmacies regarding written orders for drugs sold to regulated health professionals (Section 9(2)(a)).
  • The council's role in developing standards for licensed pharmacies regarding written orders is made subject to Ministerial orders (Section 9(4)(a), new 29.1(1.2)).

Why it matters

  • Centralizes significant regulatory authority over the sale of Schedule 1 drugs from the council of the pharmacy profession and the standard regulatory process to direct ministerial orders.
  • Removes a layer of transparency and public oversight by explicitly exempting these ministerial orders from the Regulations Act, which typically requires public notice and review.
  • Potentially impacts the autonomy of the pharmacy profession in setting standards for drug sales.
  • Creates a new mechanism for drug distribution that could have implications for patient access, safety, and professional practice.

Rights affected

  • Access to information — The ability to see public records and government decisions.

Other governance concerns

  • Ministerial discretion over drug regulation
  • Reduced transparency in regulatory process
  • Impact on professional autonomy

Primary sources (1)